Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placenta transfer factor injection plus entecavir for HBeAg-positive chronic hepatitis B
ChiCTR-IPR-15006077Phase 4Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Oct 2014
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of anti-hepatitis B virus placenta transfer factor and entecavir in Chronic Hepatitis B (CHB) (2 arms), sponsored by Peking University First Hospital. Primary endpoint: HBeAg seroconversion rate. Started Oct 2014; status: recruiting.
02
Drugs
anti-hepatitis B virus placenta transfer factorentecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR-IPR-15006077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006077.